Sep 19, 2022 · PURPOSE Selpercatinib, a first-in-class, highly selective, and potent CNS-active RET kinase inhibitor, is currently approved for the treatment of patients with RET …

Jun 11, 2021 · In this real-world setting, the selective RET-inhibitor selpercatinib demonstrated durable systemic and intracranial antitumor activity in RET fusion-positive NSCLC and was …

Sep 19, 2022 · Rearranged during transfection (RET) fusions are common genetic drivers of PTC and the potent RET inhibitor selpercatinib has been recently approved for treating advanced or …

Selpercatinib, a highly selective RET inhibitor, has demonstrated efficacy in various solid tumors harboring RET alterations. Here, we present a case highlighting the use and clinical outcomes …

Aug 27, 2020 · Conclusions: Selpercatinib had durable efficacy, including intracranial activity, with mainly low-grade toxic effects in patients with RET fusion-positive NSCLC who had previously …

Feb 21, 2025 · The safety pro le of selpercatinib was consistent with previous reports. With fi substantial additional follow-up, selpercatinib continued to show durable responses and …

Jun 11, 2021 · Methods A retrospective efficacy and safety analysis was performed on data from RET fusion-positive NSCLC patients who participated in a selpercatinib access program …

Jun 20, 2025 · Selective RET kinase inhibitors have recently shown remarkable progress for the treatment of advanced non-small cell lung and thyroid cancers. As RET alterations occur …

An updated assessment of the efficacy and safety of selpercatinib in patients with RET fusion–positive non–small-cell lung cancer treated in the phase I/II LIBRETTO-001 trial was …

Jun 23, 2025 · Adjuvant treatment for resectable non-small cell lung cancer (NSCLC) has seen significant advancements following the introduction of immune checkpoint inhibitors (ICIs). …